TIE2 (A1124V)

TEK · Variant type: point · HGVS: p.A1124V

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	98.3%	1.7%	78.23
2	Ripretinib	97.2%	2.8%	92.95
3	Tivozanib	95.4%	4.6%	92.42
4	Cabozantinib	94.5%	5.5%	92.73
5	Crizotinib	94.3%	5.7%	91.39
6	Brigatinib	90.8%	9.2%	82.96
7	Repotrectinib	89.2%	10.8%	84.21
8	Axitinib	85.9%	14.1%	93.23
9	Nintedanib	83.9%	16.1%	90.23
10	Neratinib	81.8%	18.2%	93.18
11	Erdafitinib	79.4%	20.6%	95.71
12	Infigratinib	74.7%	25.3%	98.24
13	Pemigatinib	70.9%	29.1%	98.23
14	Selpercatinib	61.1%	38.9%	96.72
15	Nilotinib	60.6%	39.4%	96.49
16	Vandetanib	56.2%	43.8%	95.74
17	Bosutinib	53.9%	46.1%	87.22
18	Defactinib	49.1%	50.9%	92.68
19	Apatinib	44.7%	55.3%	97.73
20	Pacritinib	44.0%	56.0%	88.64
21	Lenvatinib	44.0%	56.0%	97.74
22	Sorafenib	41.6%	58.4%	96.72
23	Umbralisib	40.5%	59.5%	98.74
24	Dabrafenib	36.9%	63.1%	94.74
25	Ibrutinib	35.9%	64.1%	94.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	98.3%	—	—
Ripretinib	97.2%	—	—
Tivozanib	95.4%	—	—
Cabozantinib	94.5%	—	—
Crizotinib	94.3%	—	—
Brigatinib	90.8%	—	—
Repotrectinib	89.2%	—	—
Axitinib	85.9%	—	—
Nintedanib	83.9%	—	—
Neratinib	81.8%	—	—
Erdafitinib	79.4%	—	—
Infigratinib	74.7%	—	—
Pemigatinib	70.9%	—	—
Selpercatinib	61.1%	—	—
Nilotinib	60.6%	—	—
Vandetanib	56.2%	—	—
Bosutinib	53.9%	—	—
Defactinib	49.1%	—	—
Apatinib	44.7%	—	—
Pacritinib	44.0%	—	—
Lenvatinib	44.0%	—	—
Sorafenib	41.6%	—	—
Umbralisib	40.5%	—	—
Dabrafenib	36.9%	—	—
Ibrutinib	35.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms